# A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia

> **NCT03481946** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 6 (actual)

## Conditions studied

- Hemophilia A; Hemophilia B

## Interventions

- **DRUG:** BAY1093884
- **DRUG:** BAY1093884

## Key facts

- **NCT ID:** NCT03481946
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-10
- **Primary completion:** 2018-10-17
- **Final completion:** 2019-02-20
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03481946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03481946, "A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03481946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*